Trinseo (TSE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual general meeting is scheduled for June 25, 2025, with nine director nominees up for election, and several key proposals for shareholder approval, including executive compensation, auditor ratification, share issuance authority, amendments to the incentive plan, and voluntary forfeiture of underwater options by top executives.
The company faced challenging market conditions in 2024, implementing restructuring, cost-saving initiatives, and a major debt refinancing to improve liquidity and reduce exposure to cyclical markets.
Shareholders are encouraged to vote electronically or by mail, with detailed instructions provided for both record and beneficial holders.
Voting matters and shareholder proposals
Proposals include electing nine directors, advisory approval of executive compensation, ratification of PwC as auditor, authority to issue shares, opt-out of pre-emption rights, setting treasury share price range, amendments to the Omnibus Incentive Plan, and voluntary forfeiture of certain executive stock options.
Proposals 5 and 6 require a 75% supermajority; others require a simple majority.
Shareholder proposals and director nominations for 2026 must be submitted by January 1, 2026.
Board of directors and corporate governance
The board will be reduced to nine members, with a focus on diverse industry, financial, and leadership experience.
All directors except the CEO are independent under NYSE standards.
The board separates the roles of Chair and CEO, conducts annual self-evaluations, and maintains a code of conduct and ethics.
Four standing committees: Audit, Compensation and Talent Development, Nominating and Corporate Governance, and Environmental, Health, Safety, Sustainability & Public Policy.
Latest events from Trinseo
- Q4 saw a $251M net loss, 19% sales drop, flat EBITDA, and ongoing restructuring challenges.TSE
Q4 202513 Mar 2026 - Q2 2024 Adjusted EBITDA hit a two-year high, with positive free cash flow expected in H2.TSE
Q2 20242 Feb 2026 - Q3 net loss of $87M, but Adjusted EBITDA rose $25M; liquidity and restructuring improved outlook.TSE
Q3 202415 Jan 2026 - Q4 2024 delivered higher EBITDA and cash flow, but losses persist amid weak demand and restructuring.TSE
Q4 20242 Dec 2025 - Shareholders will vote on directors, executive pay, auditor, share issuance, and incentive plan changes.TSE
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor ratification, and share issuance authority.TSE
Proxy Filing1 Dec 2025 - Q2 2025 net loss and sales decline persist, but cost actions and liquidity measures support outlook.TSE
Q2 202524 Nov 2025 - Adjusted EBITDA rose to $65M in Q1 2025, driven by licensing income and cost savings.TSE
Q1 202522 Nov 2025 - Q3 2025 net loss widened to $110 million on 14% lower sales, with major restructuring underway.TSE
Q3 202514 Nov 2025